Combination of doses, better than monotherapy for pulmonary hypertension

Published Date: 08 Mar 2023

People with hypertension (high blood pressure in the arteries that supply the lungs, also known as PAH) have up to a two-fold reduction in pulmonary vascular resistance (PVR) when taking PAH.

Read Full News

Latest News

Novel imaging approach may improve treatment for spinal cord injuries

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

Tirzepatide may only temporarily suppress brain 'food noise' activity

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

New tool predicts graft failure after kidney transplant

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

Supercomputer simulation is changing how we study the brain

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

How are patients using health care chatbots? Study finds some 'eye-openers'

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

Todays Updates

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio

Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH

The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli

A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Personalized Care Improvements Identified for Older Patients with Skin Cancer

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

What to Expect at the 2026 Maui Derm Conference

What to Expect at the 2026 Maui Derm Conference

Todays Updates

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio

Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH

The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli

A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Personalized Care Improvements Identified for Older Patients with Skin Cancer

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

What to Expect at the 2026 Maui Derm Conference

What to Expect at the 2026 Maui Derm Conference

Latest News

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

News All Time

At some doctors' offices, AI is listening in the exam room

Bracken Babula starts patient visits these days by closing the exam room door and asking if they mind him recording their conversation. He hits a button on his mobile phone, checks that it is recording, and sits back in his ...

Software optimizes brain simulations, enabling them to complete complex cognitive tasks

A new software enables brain simulations which both imitate the processes in the brain in detail and can solve challenging cognitive tasks. The program was developed by a research team at the Cluster of Excellence "Machine ...

GLP-1 and health: Beyond weight loss in the Ozempic era

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people ...

When life imitates art: Google searches for anxiety drug spike during run of The White Lotus TV show

In season three of the hit television series "The White Lotus," the character Victoria Ratliff takes the prescription anti-anxiety medication lorazepam to help with her social anxiety and inability to sleep. Her casual usage ...

Digital access improves convenience, but cannot fully replace physical services

A research team from the Urban and Transportation Systems Laboratory, Department of Architecture and Civil Engineering, Toyohashi University of Technology, has developed an innovative evaluation framework that quantitatively ...

Deep learning system could transform skin cancer detection with near-perfect accuracy

Melanoma remains one of the hardest skin cancers to diagnose because it often mimics harmless moles or lesions. While most artificial intelligence (AI) tools rely on dermoscopic images alone, they often overlook crucial patient ...

How the brain learns and applies rules: Sequential neuronal dynamics in the prefrontal cortex

Understanding how the brain learns and applies rules is the key to unraveling the neural basis of flexible behavior. A new study from the University of Toyama, Japan, reveals that our ability to follow procedural rules is ...

Computational deep dive reveals hidden cancer drug targets and repurposing opportunities

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

Wireless incubator enables remote monitoring of premature infants from 30 meters away

A wireless, portable incubator that could transform care for premature infants is reported in the International Journal of Medical Engineering and Informatics. It offers remote monitoring and automated environmental control ...

Speeding the detection of three serious regional fungal infections

Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil exposure. These infections can affect both healthy and immunocompromised people, but proper diagnosis ...

Molecular test could allow for more accurate Lyme disease diagnosis

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.

Kidney organoids uncover Hippo signaling pathway as a therapeutic target for nephronophthisis

Using human-induced pluripotent stem cell-derived kidney organoids, researchers from Science Tokyo uncovered how abnormal Hippo signaling drives fibrosis in nephronophthisis, a genetic kidney disorder caused by NPHP1 deficiency.

FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).

FDA approves Caplyta for major depressive disorder in adults

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.

Family history key to predicting antidepressant response

A new study from Queen Mary University of London shows that a family's experience with certain medicines could help doctors predict how future generations will respond to the same drugs.

Artificial intelligence, wellness apps alone cannot solve mental health crisis, warn experts

Emotional support is an increasingly common reason people turn to generative artificial intelligence chatbots and wellness applications, but these tools currently lack the scientific evidence and the necessary regulations ...

Recommended News For You

Climate change is expected to increase the number of suicide deaths

For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.

Can taking vitamin D supplements every day lower the mortality rate from cancer?

Medicaid expansion tied to smaller declines in early-stage cancer detection

How a California Oncologist Making $850k Spends Money

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

Recommended Articles For You

The latest Hematocrit: An Overview of Red Blood Cell Health  

The Cutting-Edge of Phlebectomy: Redefining Vein Care 

A Closer Look at MCV Modules: Features, Functions, and Benefits  

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

2.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

3.

Francis Collins reveals that he was diagnosed with "aggressive" prostate cancer.

4.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

5.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.

1.

New Research on Craniopharyngioma 

2.

Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy

3.

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma

4.

Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine

5.

Understanding Histiocytosis: Symptoms, Causes, and Treatment Options

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

3.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot